Founded in September 2021 and headquartered in Beijing, Yuewei Medical builds medical devices that target unmet clinical needs in cardiovascular surgery. The company has two self-developed product lines—coronary surgery and critical-care/extracorporeal circulation—covering nearly ten devices, among them an ultrasound vascular flow measurement system, a pulsatile left ventricular assist system and a double-lumen jugular catheter, all described as domestic firsts. Its pipeline also spans AI-driven diagnostics, high-end innovative hardware and import-substitution products, giving it a tiered portfolio from early to late stage. Leveraging acquisition capability, the company plans to expand into a deep-vein thrombosis (DVT) product line by 2025, adding two devices already in registrational clinical trials. Management emphasizes an “clinician-engineer” model that tightly integrates clinical insight with R&D. Though no revenue figures were disclosed, Yuewei reports that its commercial model has already been validated in China’s fragmented cardiovascular surgical market.

Total raised

$28M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2026